Kidney Cancer Weekly

October 13, 2025

Videos

Peer-to-Peer Clinical Conversations

Diagnostic Imaging and Treatment Options for Small Renal Masses - Fernando Pablo Secin

Fernando Secin

Zachary Klaassen hosts Fernando Secin to discuss the management of small renal masses.

View

ORACLE Study Explores Efficacy of Post-Combination Therapies in Non-Clear Cell RCC - Deepak Kilari

Deepak Kilari

Zachary Klaassen speaks with Deepak Kilari about the ORACLE study examining subsequent treatments after combination therapy in non-clear cell renal cell carcinoma.

View

Beyond the Abstracts

Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma - Beyond the Abstract

Metastatic Renal Cell Carcinoma: Synchronous vs. Metachronous Metastatic Disease and Its Impact on Cancer Control in the IO-Combination Era-Real World Experiences from a Multi-Institutional Cohort - Beyond the Abstract

Conference Coverage

ASTRO 2025: Ultra-Hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for Primary Renal Cell Carcinoma: Pooled Outcomes from the FASTRACK and FASTRACK II Clinical Trials

ASTRO 2025: 265 - Long-Term Follow-up Results after Stereotactic Body Radiotherapy for Primary Renal Cell Carcinoma: A Prospective Multicenter Phase 2 Trial

ASTRO 2025: Stereotactic Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer: Final Results of a Phase IIb Trial

ASTRO 2025: Discussant: Revelations in Renal Radiotherapy

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Optimal Treatment Duration in Metastatic Renal Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors: Should We Treat Beyond Two Years? - Beyond the Abstract

Delayed pancreatic metastasis from renal cell carcinoma managed with pazopanib and stereotactic ablative body radiotherapy.

Histopathology and outcomes of non-metastatic renal cell carcinoma with inferior vena cava tumor thrombus: systematic review and meta-analysis.

Clinical outcomes and prognostic factors in patients undergoing radical nephrectomy with lymphadenectomy for pN1 renal cell carcinoma.

ARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway.

Development and Validation of a Novel Plasma Metabolomic Signature for the Detection of Renal Cell Carcinoma.

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

A systematic review of global experiences with Medtronic's Hugo™ robotic system for robot-assisted partial nephrectomy.

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.

Preoperative β2 Microglobulin Is a Prognostic Factor in Patients with Renal Cell Carcinoma and Normal Kidney Function.

An International Delphi Consensus About Tumor Rupture During Robotic Partial Nephrectomy (Researching UnPredictable TUmor RupturE during Robotic Partial Nephrectomy-The RUPTURE Project).

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login